Therapeutic Glaucoma

Genotyping and artificial intelligence are together starting to predict the progression of glaucoma in individual patients, sparing them from suboptimal treatments and adverse effects. Recent research efforts are exploring modifiable risk factors such as caffeine consumption.

A research team led by the Department of Ophthalmology, School of Clinical Medicine, LKS Faculty of Medicine of The University of Hong Kong, with collaborators from the Faculty of Medicine of The Chinese University of Hong Kong and local and international partners, have developed a new technology ROTA to unveil the optical texture and trajectories of the axonal fiber bundles on the retina.

Timing of type 2 diabetes or hypertension diagnosis may impact the risk of primary open-angle glaucoma.

Bausch + Lomb has made an equity investment in Sanoculis and has entered into an exclusive European distribution agreement for MIMS minimally invasive surgical procedure.

Janet B. Serle, MD, discusses the pros and cons of various treatment options.

NCX 470 is currently enrolling patients in two multi-regional Phase 3 glaucoma clinical trials, Mont Blanc and Denali. The objective of these two trials is to demonstrate statistically superior IOP lowering of once daily dosed NCX 470

Device demonstrates potential as a durable, sustained-release glaucoma therapy

The company announced the expansion of its commercial rollout of its MIGS implant to the UK

The company is planning a Phase 2 trial with an optimized formulation in wet AMD that is expected to start in fourth quarter of 2022.

Vanderbilt’s David Calkins, PhD, was honored with the 2022 President’s Award, presented by the Glaucoma Research Foundation, at the Glaucoma 360 Annual Gala last month.

The glaucoma toolbox is expanding to include laser, drug delivery systems, and minimally invasive glaucoma surgery.

Mark Gallardo, MD, reports 12-month outcomes of iStent inject® combined with cataract surgery in a predominantly Hispanic patient population with mild to moderate open-angle glaucoma (OAG) and comorbid cataract.

Basil Williams, Jr., MD, reports on the association between development of elevated intraocular pressure and numerous commonly performed vitreoretinal treatments.

Although minimally invasive procedure gives hope, additional research is required.

Pressure-dependent optic nerve disease, retinal disease.

Two trials examine factors affecting the risk of disease.

MIGS drainage device offers hope for challenging cases.

Exploring subtleties helps ophthalmologists understand postop surprises, drug reactions.

Measurements from multiple studies show benefits of rho-kinase inhibition.

Visible-light optical coherence tomography proves valuable in studies.

Details enhance knowledge of biological pathways that contribute to disease pathogenesis.

Option could prove to enhance safety for both patients and staff.

Use of such procedures increased markedly in analysis of IRIS Registry Data.

Virtual reality, home visual field testing offer new options for physicians.

Ophthalmologist details his preferred technique to avoid complications during procedure.

Short learning curve, significant clinical advantages make this a comfortable addition.

IOP-controlling protein in the trabecular meshwork may get the fluid moving.

Investigators find treatment is an option for treating open-angle glaucoma.

A supraciliary minimally invasive glaucoma procedure may offer a valuable bleb-free treatment option for patients with glaucoma that requires low target pressures.